Literature DB >> 29623306

Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma.

Neerav Shukla1, Stephen S Roberts1, Mollah O Baki2, Qazi Mushtaq2, Paul E Goss3, Ben H Park4, Gunes Gundem5, Ken Tian6, Heather Geiger6, Kristie Redfield7, Gerald Behr8, Ryma Benayed9, Ahmet Zehir9, Jaclyn F Hechtman9, Robert B Darnell6,10,11, Elli Papaemmanuil5, Marc Ladanyi9, Nora Ku12, Andrew L Kung1, José Baselga13, Alexander Drilon13, David M Hyman13.   

Abstract

Entities:  

Keywords:  Targeted therapy; cancer genomics; global health; larotrectinib; pediatric cancer; secretory breast carcinoma

Year:  2017        PMID： 29623306      PMCID： PMC5880290          DOI： 10.1200/PO.17.00034

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  23 in total

1.  Anchored multiplex PCR for targeted next-generation sequencing.

Authors:  Zongli Zheng; Matthew Liebers; Boryana Zhelyazkova; Yi Cao; Divya Panditi; Kerry D Lynch; Juxiang Chen; Hayley E Robinson; Hyo Sup Shim; Juliann Chmielecki; William Pao; Jeffrey A Engelman; A John Iafrate; Long Phi Le
Journal:  Nat Med       Date:  2014-11-10       Impact factor: 53.440

2.  The genomic landscape of pediatric Ewing sarcoma.

Authors:  Brian D Crompton; Chip Stewart; Amaro Taylor-Weiner; Gabriela Alexe; Kyle C Kurek; Monica L Calicchio; Adam Kiezun; Scott L Carter; Sachet A Shukla; Swapnil S Mehta; Aaron R Thorner; Carmen de Torres; Cinzia Lavarino; Mariona Suñol; Aaron McKenna; Andrey Sivachenko; Kristian Cibulskis; Michael S Lawrence; Petar Stojanov; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Sara Seepo; Brendan Blumenstiel; Matthew DeFelice; Ivan Imaz-Rosshandler; Angela Schwarz-Cruz Y Celis; Miguel N Rivera; Carlos Rodriguez-Galindo; Mark D Fleming; Todd R Golub; Gad Getz; Jaume Mora; Kimberly Stegmaier
Journal:  Cancer Discov       Date:  2014-09-03       Impact factor: 39.397

Review 3.  Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature.

Authors:  Dali Li; Xiuying Xiao; Wentao Yang; Ruohong Shui; Xiaoyu Tu; Hongfen Lu; Daren Shi
Journal:  Mod Pathol       Date:  2011-12-09       Impact factor: 7.842

4.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.

Authors:  Cristina Tognon; Stevan R Knezevich; David Huntsman; Calvin D Roskelley; Natalya Melnyk; Joan A Mathers; Laurence Becker; Fatima Carneiro; Nicol MacPherson; Doug Horsman; Christopher Poremba; Poul H B Sorensen
Journal:  Cancer Cell       Date:  2002-11       Impact factor: 31.743

5.  An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Authors:  Robert C Doebele; Lara E Davis; Aria Vaishnavi; Anh T Le; Adriana Estrada-Bernal; Stephen Keysar; Antonio Jimeno; Marileila Varella-Garcia; Dara L Aisner; Yali Li; Philip J Stephens; Deborah Morosini; Brian B Tuch; Michele Fernandes; Nisha Nanda; Jennifer A Low
Journal:  Cancer Discov       Date:  2015-07-27       Impact factor: 39.397

6.  ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex.

Authors:  Zhe Li; Cristina E Tognon; Frank J Godinho; Laura Yasaitis; Hanno Hock; Jason I Herschkowitz; Chris L Lannon; Eunah Cho; Seong-Jin Kim; Roderick T Bronson; Charles M Perou; Poul H Sorensen; Stuart H Orkin
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

7.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

8.  Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Authors:  A Vaishnavi; M Capelletti; P A Jänne; R C Doebele; A T Le; S Kako; M Butaney; D Ercan; S Mahale; K D Davies; D L Aisner; A B Pilling; E M Berge; J Kim; H Sasaki; S Park; G Kryukov; L A Garraway; Peter S Hammerman; J Haas; S W Andrews; D Lipson; P J Stephens; V A Miller; M Varella-Garcia
Journal:  Nat Med       Date:  2013-10-27       Impact factor: 53.440

9.  What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Authors:  A Drilon; G Li; S Dogan; M Gounder; R Shen; M Arcila; L Wang; D M Hyman; J Hechtman; G Wei; N R Cam; J Christiansen; D Luo; E C Maneval; T Bauer; M Patel; S V Liu; S H I Ou; A Farago; A Shaw; R F Shoemaker; J Lim; Z Hornby; P Multani; M Ladanyi; M Berger; N Katabi; R Ghossein; A L Ho
Journal:  Ann Oncol       Date:  2016-02-15       Impact factor: 32.976

10.  Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Authors:  Ramamoorthy Nagasubramanian; Julie Wei; Paul Gordon; Jeff C Rastatter; Michael C Cox; Alberto Pappo
Journal:  Pediatr Blood Cancer       Date:  2016-04-19       Impact factor: 3.167
View more
  12 in total

Review 1.  TRK Inhibitors: Clinical Development of Larotrectinib.

Authors:  Munveer S Bhangoo; Darren Sigal
Journal:  Curr Oncol Rep       Date:  2019-02-04       Impact factor: 5.075

2.  Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma.

Authors:  A M Schram; P Jonsson; A Drilon; T A Bale; J F Hechtman; R Benayed; B Hanusch; R J Young; C Grommes; N Ku; T Kaley; D M Hyman; B S Taylor
Journal:  JCO Precis Oncol       Date:  2018-08-08

3.  José Baselga M.D., Ph.D. (1959-2021) leading cancer researcher and oncologist.

Authors:  Moshe Elkabets; Giovanni Blandino
Journal:  J Exp Clin Cancer Res       Date:  2021-05-07

Review 4.  Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance.

Authors:  Suet Kee Loo; Megan E Yates; Sichun Yang; Steffi Oesterreich; Adrian V Lee; Xiao-Song Wang
Journal:  Genes Chromosomes Cancer       Date:  2022-02-17       Impact factor: 5.006

Review 5.  Pure secretory carcinoma in situ: a case report and literature review.

Authors:  Ying Yang; Zhiyuan Wang; Guoqing Pan; Shumo Li; Yingying Wu; Liu Liu
Journal:  Diagn Pathol       Date:  2019-08-23       Impact factor: 2.644

Review 6.  Secretory breast carcinoma in a female adult with liver metastsis: a case report and literature review.

Authors:  Jing Lian; Li-Xia Wang; Jiang-Hong Guo; Peng Bu; Yan-Feng Xi; Ke-Ming Yun
Journal:  Diagn Pathol       Date:  2021-10-10       Impact factor: 2.644

Review 7.  Secretory carcinoma of the breast with multiple distant metastases in the brain and unfavorable prognosis: a case report and literature review.

Authors:  Hongping Tang; Lihua Zhong; Hongbing Jiang; Yan Zhang; Guannan Liang; Guoyan Chen; Gui'e Xie
Journal:  Diagn Pathol       Date:  2021-06-24       Impact factor: 2.644

Review 8.  Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations.

Authors:  Dara S Ross; Fresia Pareja
Journal:  Surg Pathol Clin       Date:  2021-07-08

Review 9.  NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine.

Authors:  Federica Zito Marino; Francesca Pagliuca; Andrea Ronchi; Immacolata Cozzolino; Marco Montella; Massimiliano Berretta; Maria Elena Errico; Vittoria Donofrio; Roberto Bianco; Renato Franco
Journal:  Int J Mol Sci       Date:  2020-05-25       Impact factor: 5.923

Review 10.  Rare epithelial breast cancer: surgery and adjuvant therapy.

Authors:  Aida Abdelwahed; Muneer Ahmed
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.